Review Articles





Sai Datri Arige, Lakshmana Rao A

ABSTRACT: Ulcers are caused by imbalance between the gastro duodenal mucosal defensive factors such as bicarbonate, mucus versus aggressive factors like acid and pepsin secretion. The drug treatment of peptic ulcer has significantly brought down the morbidity and mortality and need of surgical interventions which may be attributed to the advent of H2 blockers and proton pump inhibitors. These symptoms frequently occur several hours following a meal, after the food leaves the stomach but while acid production is still high. Instead of pain, some patients experience intense hunger or bloating. Many animal models are using to induce ulcer to identify the antiulcer property of many new and existed drugs such as Pyloras ligated rat, Stress ulcers, Histamine induced gastric ulcers, Cysteamine induced duodenal ulcers and Dulcerozine induced duodenal ulcers.

KEYWORDS: Peptic ulcer, duodenal ulcer and inflammation.



  1. Hojgaard L, Nielsen AM, Rune SJ. Peptic ulcer pathophysiology: Acid bicarbonate, and mucosal function. Scandinavian Journal of Gastroenterology, 1996; 31(1): 10-15.

  2. Snowdex FM. Emerging and re-emerging: “Historical and perspective”. Immunological Reviews, 2008; 225: 9-26.

  3. Isenberg JI, Flemstrom G. Physiology and pathophysiology of gastro duodenal bicarbonate secretion. Digestive Diseases. 1991; 23: 27-33.

  4. Agurav M, Rimpi A, Shaba P. Study Different Experiment Models Used In Peptic Ulcer. International Journal of Recent Advances In Pharmaceutical Research. 2015; 5(2): 31-37.

  5. Shirisha B, Subash V. Animal Models in Experimental Gastric Ulcer Screening -A Review. International Research Journal of Pharmacy. 2012; 3(6): 57-77.

  6. Graham DY, Rakel RE, Fendrick AM. Recognizing peptic ulcer disease: keys to clinical and laboratory diagnosis. Postgraduate Medical 1999; 105(3): 113-133.

  7. Harsh Mohan. Text book of pathology.Jaypee publishers; 2009. 549-555 p.

  8. Mahajan N, Sanghai D. Evaluation of anti-uler potential of leaves of Jasminumgrandiflorum L. International Journal of Pharmaceutical Sciences. 2009; 1(9): 247-249.

  9. Ludovico B, Eric S, Annemarthe G, Van DV, Rino R, Antonello C. Helicobacter Pylori cytotoxinassociated gene A subverts the apoptosis-stimating protein of p53ASPP 2tumor suppressor pathway of the host. Proceedings of the National Academy of Sciences of the United States of America. 2011;

  10. Martin JB. Not all Helicobacter pylori strains are created equal; should all be liminated. The Lancet. 1997; 349: 1020-22.

  11. Fan XG, Kelleher D, Fan XJ, Xia HX, Keeling PW. Helicobacter pylori increases proliferation of gastric epithelial cells. Gut. 1996; 38: 19-22.

  12. Marshall B, Warren JR. Unidentified curved bacillus in active chronic gastritis. Lancet. 1983; 1.

  13. Akram M. Peptic ulcer and Helicobacter pylori eradication: A review article. . 2010; 2: 370 -375.

  14. Szabo S, Vincze A, Sandor Z, Jadus M, Gombos Z, Pedram A. Vascular approach to gastroduodenal ulceration. New stud-ies with endothelins and VEGF. . 1998; 43: 40-45.

  15. Aihara T, Nakamura E, Amagase K, Tomita K, Fujishita T, Furutani K. Pharmacological control of gastric acid secretion for the treatment of acid -related peptic disease: past, present, and future. Pharmacology 2003; 98: 109.

  16. Tasman JC. Pathogenesis of peptic ulcer disease and gastritis: Importance of aggressive and cytoprotective factors. Scandinavian 1986; 21: 1-5.

  17. Lindstrom E, Chen D, Norlen P, Andersson K, Hakanson R. Control of gastric acid secretion: the gastrin-ECL cell -parietal cell axis. Comparative Biochemistry and Physiology. 2001; 128: 505–514.

  18. Chey WD, Wong BC. American College of Gastroenterology guideline on the anagement of Helicobacter pyloriinfection. . 2007; 102(8):1808-1825.

  19. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane database of systematic reviews. 2006; 19(2): 38-40.

  20. Terence C, Enrique R. CCK2 receptor mediates rapid protein kinase D activation through a protein kinase C-dependent pathway. FEBS Letters. 2001; 89: 101-106.

  21. Waldum HL, Kleveland PM, Sandvik AK, Brenna E, Syversen U, Bakke I, Tommeras K. The cellular localization of the cholecystokinin 2 receptor in the stomach. Journal of Pharmacology and Toxicology. 2002; 91: 359–362.

  22. Talley NJ, Vakil N. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005; 129(5): 1756-1780.